The Elipse™ Next-Generation Intragastric Balloon

A Weight Loss Device Placed in a Doctor’s Office

Indian Market Opportunity | December 2014

 THE ELIPSE™ NEXT-GENERATION INTRAGASTRIC BALLOON

Opportunity Overview

• Allurion Technologies is a privately held, Boston-based medical device

company that has developed the Elipse™, a breakthrough weight loss device
that can be placed in a physician’s office.
• Unlike any other weight loss device, neither placement nor removal of the
Elipse™ requires surgery or endoscopy.
• The Elipse™ reduces stomach volume and slows the rate of food digestion.
After three months it passes from the stomach and exits the body naturally.
• Elipse™ will be positioned in the private-pay market.
• Human clinical trials are ongoing and European “CE Mark” regulatory
approval is expected in mid-2015.
• Allurion Technologies is interested in joining with one or more local
partners to create a stand-alone commercial entity in the Indian market.
• The Indian newco will hold an exclusive, perpetual, non royalty-bearing
license to manufacture and market the Elipse™ in India.
• Funding this entity will enable an accelerate approach to CDSCO with
potential Indian commercial launch targeted for early 2016.

© 2014 ALLURION TECHNOLOGIES 1

 INTRAGASTRIC BALLOON BASICS

• Intragastric balloons (IGBs) are weight loss devices

that have historically been placed and removed
under endoscopic guidance.

• Balloons are smooth, spherical and are typically filled

with 500ml - 700ml of saline.

• IGBs involve no anatomic modification. They create a powerful but

temporary modification of the digestive system.

• Obese patients average 14.7 kg of weight loss

over six months1, 80% of which is achieved
in three months.

• Side effects typically include up to 3 days of

self-limiting nausea and vomiting.

• Endoscopic IGB treatment is widely available

OUS today and is expected in the US in 2015.

1Imaz et.al., 2007 meta-analysis of 15 studies comprising balloon plus diet in 3,608 patients
© 2014 ALLURION TECHNOLOGIES 2
THE ELIPSE™ IS A NEXT-GENERATION INTRAGASTRIC BALLOON

• Same proven mechanism of action as well-known,

endoscopically administered and removed IGBs

• Provided and removed without endoscopy

• Made entirely from thin, flexible materials

designed to smoothly transit the GI tract

• Provided to patients in a soft oral

dosage form for easy swallowing

• Placed and filled during a

20 minute in-office procedure

• Naturally deflates after three month

treatment period and passes out
of the stomach

• Transits distal GI tract and is excreted

© 2014 ALLURION TECHNOLOGIES 3

 IGBs OUTPERFORM DIET AND SHAM IN CLINICAL TRIALS

Sham-Controlled Crossover Study1 Diet Controlled Study2

46
40
SHAM
44 38
42 DIET ALONE
IGB 36
40 34
BMI

BMI
IGB
38 32
SHAM IGB + DIET DIET ALONE
36 30
34 28
32 26
0 3 6 0 3 6 9 12
Month Month

1Genco et al, 2006. 2Fuller et al, 2013.

© 2014 ALLURION TECHNOLOGIES 4

 IGB THERAPY ALSO IMPROVES METABOLIC COMORBIDITIES

Hypercholesterolemia -50% Before

After
Hypertriglyceridemia -62%

Hypertension -32%

Metabolic Syndrome -58%

Type II Diabetes -36%

0% 10% 20% 30% 40% 50%

Adapted from Crea et.al. 2009 based on six month therapy; Up to Date

© 2014 ALLURION TECHNOLOGIES 5

ELIPSE IS DELIVERED IN-OFFICE AND EXCRETED NATURALLY

Elipse is
swallowed Expanded
naturally in the stomach

Remains in
Passes stomach
naturally reducing desire
for food

© 2014 ALLURION TECHNOLOGIES 6

 ELIPSE™ IS THE ONLY OFFICE-BASED
WEIGHT LOSS PROCEDURE

Short Term Medium Long Term

3-9 mos 1-3 years 10+ years

Office-Based

Endoscopic

Gastric Sleeve
Surgical
Bypass

© 2014 ALLURION TECHNOLOGIES 7

 TARGETING REGULATORY APPROVALS
AND FIRST COMMERCIAL REVENUE IN 2015

2013 2014 2015 2016

OUS Trials FIM MULTI CENTER

CE Marking (EU)

Approval in
Other Markets

Market Launches

US FDA Process

© 2014 ALLURION TECHNOLOGIES 8

 THE ELIPSE™ OFFERS A STRONG VALUE PROPOSITION
FOR MULTIPLE STAKEHOLDERS
Patients and Payors

• 10 kg (~22 lb) weight loss over three months

• Excellent safety profile
• No surgery, endoscopy or sedation
• Priced accessibly to self-pay market

Practitioners

• Minimal specialized training required

• Bolt-on revenue stream to existing practice
• Non-specialist delivery amenable to emerging markets

Shareholders

• Indian overweight and diabetes market growing rapidly

• Ability to roll out quickly to multiple sites
• Extraordinary revenue potential

© 2014 ALLURION TECHNOLOGIES 9

 POTENTIAL STRUCTURE FOR ALLURION-INDIA NEWCO

Financial
Allurion Partner*
Technologies Inc. Operating
Partner*

Management

Product 30% 10% 60% Local

and Clinical Market
Expertise Expertise

Allurion – India Newco

Holds exclusive, perpetual, non-

royalty bearing license to market
Elipse™ and all improvements

* May be one or multiple parties

© 2014 ALLURION TECHNOLOGIES 10
 THE ALLURION TEAM

Jonathan Wecker, Chief Executive Officer. Joined Allurion in 2010. Former CEO of AIGB True
Results® weight loss surgery centers. Corporate experience from Salomon Brothers, the Boston
Consulting Group and Bain Capital. MBA, Harvard Business School.
Dr. Shantanu Gaur, Chief Scientific Officer. Co-founded Allurion in 2009. MD, Harvard
Medical School (2013). Genetic Alliance Board member, Paul & Daisy Soros Fellow. S.B. in
Biology, Harvard College summa cum laude and Phi Beta Kappa.
Dr. Samuel Levy, President. Co-founded Allurion in 2009. MD, Harvard Medical School (2012).
Fulbright scholar and former McKinsey & Co. consultant. B.S. in Molecular Biophysics and
Biochemistry, Yale College summa cum laude and Phi Beta Kappa.
Matthew Lake, PE, Director of Engineering and Manufacturing. Joined Allurion in 2013.
Previously Principal R&D Engineer at Obalon Therapeutics. MBA, Suffolk University and B.S.E
in Mechanical Engineering, University of Michigan.
Vince Panzano, PhD, Director of Quality Assurance. Joined Allurion in 2013. Ph.D in
Neuroscience from Brandeis University. B.A. in Cognitive Science, Yale College.
Dr. Kathy Stecco, Head of Clinical Affairs. Joined Allurion in 2012 (pt). Trained at Stanford
Medical School as a general surgeon. Extensive obesity and GI device trial management
experience.
Dr. Ram Chuttani, Senior Medical Advisor. Joined Allurion in 2010. Director of Endoscopy,
Chief of Interventional Gastroenterology and Board Trustee at Beth Israel Deaconess Medical
Center. Assistant Professor at Harvard Medical School. Founder, board member or consultant
for over ten GI-oriented device companies and innovative start-ups.

© 2014 ALLURION TECHNOLOGIES 11

 For further information please contact:

In the US In Europe
Jonathan Wecker Dr. Samuel Levy
Chief Executive Officer Co-Founder
888 Worcester Street Suite 320 100 Avenue de Villiers
Wellesley, MA 02482 75017 Paris, France
jwecker@allurion.com slevy@allurion.com
1 (781) 235-7050 office +33 (0)7 62 13 63 67 office
1 (617) 721-0406 cell +1 (617) 715-6926 cell